The treatment of chronic depression, Part 1: Study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies

A. John Rush, Lorrin M. Koran, Martin B. Keller, John C. Markowitz, Wilma M. Harrison, Robert J. Miceli, Jan A. Fawcett, Alan J. Gelenberg, Robert M A Hirschfeld, Daniel N. Klein, James H. James, James P. McCullough, Alan F. Schatzberg, Michael E. Thase

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Background: Chronic depressions are common, disabling, and undertreated, and prior chronicity predicts future chronicity. However, few studies directly inform the acute or maintenance phase treatments of chronic depressions and even less is known about the effects of treatment on psychosocial functioning. Method: We describe the design and rationale for 2 parallel double-blind, randomized, multicenter acute and maintenance phase treatment trials. One focused on DSM-III-R major depression currently in a chronic (≥ 2 years) major depressive episode, the other on DSM-III-R major depression with concurrent DSM-III-R dysthymia ('double depression'). Results: Considering the critical knowledge deficits, we designed a 12-week acute phase safety and efficacy trial of sertraline versus imipramine, followed by a 16-week continuation treatment phase for subjects with a satisfactory therapeutic response. Patients receiving sertraline who successfully completed the continuation phase entered a 76-week maintenance trial to compare sertraline with placebo; those taking imipramine continued without a placebo substitution. As part of the acute trial, subjects completing but failing to respond to the initial 12-week acute phase medication were crossed over (double-blind) to the alternative medication for a 12-week acute phase trial. We obtained naturalistic follow-up data (up to 18 months) for subjects exiting the protocol at any time. Conclusion: Multiphase protocols for chronic depression can test efficacy by randomized contrasts as well as shed light on key clinical issues such as the degree of response or attrition expected at particular times in a trial or the preferred medication sequence in a potential multistep treatment program.

Original languageEnglish (US)
Pages (from-to)589-597
Number of pages9
JournalJournal of Clinical Psychiatry
Volume59
Issue number11
StatePublished - Nov 1998

Fingerprint

Sertraline
Imipramine
Maintenance
Diagnostic and Statistical Manual of Mental Disorders
Therapeutics
Placebos
Safety

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

The treatment of chronic depression, Part 1 : Study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. / Rush, A. John; Koran, Lorrin M.; Keller, Martin B.; Markowitz, John C.; Harrison, Wilma M.; Miceli, Robert J.; Fawcett, Jan A.; Gelenberg, Alan J.; Hirschfeld, Robert M A; Klein, Daniel N.; James, James H.; McCullough, James P.; Schatzberg, Alan F.; Thase, Michael E.

In: Journal of Clinical Psychiatry, Vol. 59, No. 11, 11.1998, p. 589-597.

Research output: Contribution to journalArticle

Rush, AJ, Koran, LM, Keller, MB, Markowitz, JC, Harrison, WM, Miceli, RJ, Fawcett, JA, Gelenberg, AJ, Hirschfeld, RMA, Klein, DN, James, JH, McCullough, JP, Schatzberg, AF & Thase, ME 1998, 'The treatment of chronic depression, Part 1: Study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies', Journal of Clinical Psychiatry, vol. 59, no. 11, pp. 589-597.
Rush, A. John ; Koran, Lorrin M. ; Keller, Martin B. ; Markowitz, John C. ; Harrison, Wilma M. ; Miceli, Robert J. ; Fawcett, Jan A. ; Gelenberg, Alan J. ; Hirschfeld, Robert M A ; Klein, Daniel N. ; James, James H. ; McCullough, James P. ; Schatzberg, Alan F. ; Thase, Michael E. / The treatment of chronic depression, Part 1 : Study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. In: Journal of Clinical Psychiatry. 1998 ; Vol. 59, No. 11. pp. 589-597.
@article{32e79ac890ea46648ffa479a550099f5,
title = "The treatment of chronic depression, Part 1: Study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies",
abstract = "Background: Chronic depressions are common, disabling, and undertreated, and prior chronicity predicts future chronicity. However, few studies directly inform the acute or maintenance phase treatments of chronic depressions and even less is known about the effects of treatment on psychosocial functioning. Method: We describe the design and rationale for 2 parallel double-blind, randomized, multicenter acute and maintenance phase treatment trials. One focused on DSM-III-R major depression currently in a chronic (≥ 2 years) major depressive episode, the other on DSM-III-R major depression with concurrent DSM-III-R dysthymia ('double depression'). Results: Considering the critical knowledge deficits, we designed a 12-week acute phase safety and efficacy trial of sertraline versus imipramine, followed by a 16-week continuation treatment phase for subjects with a satisfactory therapeutic response. Patients receiving sertraline who successfully completed the continuation phase entered a 76-week maintenance trial to compare sertraline with placebo; those taking imipramine continued without a placebo substitution. As part of the acute trial, subjects completing but failing to respond to the initial 12-week acute phase medication were crossed over (double-blind) to the alternative medication for a 12-week acute phase trial. We obtained naturalistic follow-up data (up to 18 months) for subjects exiting the protocol at any time. Conclusion: Multiphase protocols for chronic depression can test efficacy by randomized contrasts as well as shed light on key clinical issues such as the degree of response or attrition expected at particular times in a trial or the preferred medication sequence in a potential multistep treatment program.",
author = "Rush, {A. John} and Koran, {Lorrin M.} and Keller, {Martin B.} and Markowitz, {John C.} and Harrison, {Wilma M.} and Miceli, {Robert J.} and Fawcett, {Jan A.} and Gelenberg, {Alan J.} and Hirschfeld, {Robert M A} and Klein, {Daniel N.} and James, {James H.} and McCullough, {James P.} and Schatzberg, {Alan F.} and Thase, {Michael E.}",
year = "1998",
month = "11",
language = "English (US)",
volume = "59",
pages = "589--597",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "11",

}

TY - JOUR

T1 - The treatment of chronic depression, Part 1

T2 - Study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies

AU - Rush, A. John

AU - Koran, Lorrin M.

AU - Keller, Martin B.

AU - Markowitz, John C.

AU - Harrison, Wilma M.

AU - Miceli, Robert J.

AU - Fawcett, Jan A.

AU - Gelenberg, Alan J.

AU - Hirschfeld, Robert M A

AU - Klein, Daniel N.

AU - James, James H.

AU - McCullough, James P.

AU - Schatzberg, Alan F.

AU - Thase, Michael E.

PY - 1998/11

Y1 - 1998/11

N2 - Background: Chronic depressions are common, disabling, and undertreated, and prior chronicity predicts future chronicity. However, few studies directly inform the acute or maintenance phase treatments of chronic depressions and even less is known about the effects of treatment on psychosocial functioning. Method: We describe the design and rationale for 2 parallel double-blind, randomized, multicenter acute and maintenance phase treatment trials. One focused on DSM-III-R major depression currently in a chronic (≥ 2 years) major depressive episode, the other on DSM-III-R major depression with concurrent DSM-III-R dysthymia ('double depression'). Results: Considering the critical knowledge deficits, we designed a 12-week acute phase safety and efficacy trial of sertraline versus imipramine, followed by a 16-week continuation treatment phase for subjects with a satisfactory therapeutic response. Patients receiving sertraline who successfully completed the continuation phase entered a 76-week maintenance trial to compare sertraline with placebo; those taking imipramine continued without a placebo substitution. As part of the acute trial, subjects completing but failing to respond to the initial 12-week acute phase medication were crossed over (double-blind) to the alternative medication for a 12-week acute phase trial. We obtained naturalistic follow-up data (up to 18 months) for subjects exiting the protocol at any time. Conclusion: Multiphase protocols for chronic depression can test efficacy by randomized contrasts as well as shed light on key clinical issues such as the degree of response or attrition expected at particular times in a trial or the preferred medication sequence in a potential multistep treatment program.

AB - Background: Chronic depressions are common, disabling, and undertreated, and prior chronicity predicts future chronicity. However, few studies directly inform the acute or maintenance phase treatments of chronic depressions and even less is known about the effects of treatment on psychosocial functioning. Method: We describe the design and rationale for 2 parallel double-blind, randomized, multicenter acute and maintenance phase treatment trials. One focused on DSM-III-R major depression currently in a chronic (≥ 2 years) major depressive episode, the other on DSM-III-R major depression with concurrent DSM-III-R dysthymia ('double depression'). Results: Considering the critical knowledge deficits, we designed a 12-week acute phase safety and efficacy trial of sertraline versus imipramine, followed by a 16-week continuation treatment phase for subjects with a satisfactory therapeutic response. Patients receiving sertraline who successfully completed the continuation phase entered a 76-week maintenance trial to compare sertraline with placebo; those taking imipramine continued without a placebo substitution. As part of the acute trial, subjects completing but failing to respond to the initial 12-week acute phase medication were crossed over (double-blind) to the alternative medication for a 12-week acute phase trial. We obtained naturalistic follow-up data (up to 18 months) for subjects exiting the protocol at any time. Conclusion: Multiphase protocols for chronic depression can test efficacy by randomized contrasts as well as shed light on key clinical issues such as the degree of response or attrition expected at particular times in a trial or the preferred medication sequence in a potential multistep treatment program.

UR - http://www.scopus.com/inward/record.url?scp=0031729928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031729928&partnerID=8YFLogxK

M3 - Article

C2 - 9862605

AN - SCOPUS:0031729928

VL - 59

SP - 589

EP - 597

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 11

ER -